Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2017-06-26
Target enrollment:
Participant gender:
Summary
Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel
group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate
the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to
its vehicle.